Cancer Institute Quality Measure Performance Rates
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
ACT BCSRT C12RLN G15RLN GCTRT
LCT
MAC MadjRx RCRM RECRTCT
ACT
BCSRT
C12RLN
G15RLN
GCTRT
LCT
MAC
MadjRx
RCRM RECRTCT
83% 61% 97% 74% 61% 73% 91% 84% 92% 82%
2022 CoC Academic Medical Centers Data
83% 65% 95% 71% 64% 74% 91% 86% 92% 85%
2022 CoC All NCDB Data
100% 60% 98% 86% 50% 67% 94% 90% 92% 100%
2022 UTMC CI Data
American College of Surgeons Commission on Cancer Quality of Care Measures The Commission on Cancer develops quality measures and requires all CoC-accredited programs to treat cancer patients according to these nationally accepted standards. The medical center has been CoC accredited since 1980. The performance of an individual program can be measured against the data from all other CoC-accredited programs (1,500 cancer centers in the U.S.) through the National Cancer Database.
ACT Adjuvant chemotherapy is recommended or administered within four months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer BCSRT Radiation therapy is administered within one year (365 days) of diagnosis for women under age 70 receiving breast- conserving surgery for breast cancer
C12RLN At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer G15RLN At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer
GCTRT Neoadjuvant chemotherapy and/or chemoradiation is administered within 120 days preoperatively for patients with AJCC cT2+ or cN1+, cM0 for gastric carcinoma; or (cT2 and poor differentiation) or cT3+ or cN1+, cM0 for esophageal or gastroesophageal junction carcinoma; age 18-79 LCT Systemic chemotherapy is administered within four months to day of surgery to six months postoperatively, or it is Fall 2014 recommended for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC MAC Combination chemotherapy or chemoimmunotherapy (if HER2 positive), is recommended or administered within four months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or stage IB - III hormone receptor negative breast cancer MadjRX Melanoma adjuvant systemic therapy was administered within six months of surgery or recommended for eligible patients with Stage IIIB-D resected melanoma RCRM Circumferential margin is greater than 1 mm from the tumor to the inked, non-serosalized resection margin for rectal resections RECRTCT Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer
Cancer Institute Annual Report | 33
Made with FlippingBook interactive PDF creator